ISDA: 6BNS

Deposition Date 2017-11-17

Release Date 2017-12-20

Last Version Date 2024-03-13

Entry Detail

PDB ID:

6BNS

Keywords:

NUCLEAR PROTEIN

Title:

STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide and Compound 25a AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.56 Å

R-Value Free:

0.24

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Nuclear receptor subfamily 1 group I member 2,Nuclear receptor coactivator 1 Chimera
Gene (Uniprot):NR1I2, NCOA1
Chain IDs:A, B
Chain Length:351
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O75469,Q15788 Pfam ID:PF00104, PF08832 EC:2.3.1.48

Ligand Molecules

XGH

Primary Citation

Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR gamma /RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.

Gong, H, Weinstein, D.S, Lu, Z, Duan, J.J, Stachura, S, Haque, L, Karmakar, A, Hemagiri, H, Raut, D.K, Gupta, A.K, Khan, J, Camac, D, Sack, J.S, Pudzianowski, A, Wu, D.R, Yarde, M, Shen, D.R, Borowski, V, Xie, J.H, Sun, H, D'Arienzo, C, Dabros, M, Galella, M.A, Wang, F, Weigelt, C.A, Zhao, Q, Foster, W, Somerville, J.E, Salter-Cid, L.M, Barrish, J.C, Carter, P.H, Dhar, T.G.M.Show

Bioorg. Med. Chem. Lett. 28 85 93 (2018)

PMID: 29233651 DOI: 10.1016/j.bmcl.2017.12.006

Abstact

We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form